“By understanding ferroptosis and how cells defend against it, we can develop therapeutic strategies to block those defense mechanisms and trigger cell death,” said senior author Boyi Gan, Ph.D., associate professor of Experimental Radiation Oncology. “We have discovered that DHODH plays a key role in defending against ferroptosis and shown that we can exploit this vulnerability with clinically tested therapies.”
Ferroptosis is a recently identified form of controlled cell death triggered by the toxic accumulation of lipid peroxides in the cell. Because lipid peroxides are generated through normal metabolic activities, cells also have mechanisms in place to defend against ferroptosis. Glutathione peroxidase 4 (GPX4) is one of the key defense mechanisms identified to date.
In this study, the researchers used GPX4 inhibitors to block its activity and to identify new defense mechanisms. Metabolic analyses pointed them to DHODH, a mitochondrial enzyme that normally is involved in the pyrimidine biosynthesis pathway.
In cells with low GPX4 expression, loss of DHODH activity led to the accumulation of lipid peroxides in mitochondria and the activation of ferroptosis. By contrast, cells with high GPX4 expression were able to continue blocking ferroptosis activity in the absence of DHODH. The findings suggest that DHODH and GPX4 work as redundant defense mechanisms in the mitochondria to prevent ferroptosis.
The researchers further clarified DHODH’s role in regulating ferroptosis and then investigated the therapeutic potential of targeting this enzyme in cancer cells. Using extensive preclinical models, they evaluated the DHODH inhibitor brequinar, which has been tested in multiple clinical trials for other indications.
In GPX4-low cancers, brequinar effectively induced ferroptosis and suppressed tumor growth, but the effects were not seen in GPX4-high cancers. However, the combination of brequinar and sulfasalazine, an FDA-approved ferroptosis inducer, resulted in a synergistic effect to overcome high GPX4 expression and to block tumor growth.
“We were able to leverage our understanding of a new ferroptosis defense mechanism into a novel therapeutic strategy that appears promising in preclinical studies,” Gan said. “Because ferroptosis is active across cancer types, we believe this could have broad implications, particularly in cancers with low expression of GPX4.”
The research team, currently working with physicians to plan future clinical studies to evaluate this treatment approach, continues preclinical studies to test DHODH inhibition in combination with other therapeutic modalities, such as radiation therapy.
This research was supported by institutional research funding from MD Anderson, MD Anderson’s Moon Shots Program®, the National Institutes of Health (NIH) (R01CA181196, R01CA190370, R01CA244144, R01CA247992 and P30CA016672), and The University of Texas SPORE in Lung Cancer (P50 CA070907).
Collaborating MD Anderson authors on the study include: Chao Mao, Ph.D., Xiaoguang Liu, Ph.D., Yilei Zhang, Ph.D., Guang Lei, Yuelong Yan, Ph.D., Hyemin Lee, Ph.D., Pranavi Koppula, Shiqi Wu, and Li Zhuang, all of Experimental Radiation Oncology; and Bingliang Fang, M.D., Ph.D., of Thoracic and Cardiovascular Surgery. Additional authors include: Masha V. Poyurovsky, Ph.D., and Kellen Olszewski, Ph.D., both of Kadmon Corporation, LLC, New York, NY. A list of their disclosures can be found here.
